Comparing the current results to its competitors, Boston Scientific reported Revenue increase in the 1 quarter 2026 by 11.6 % year on year. The sales growth was above Boston Scientific's competitors' average revenue growth of 7.2 %, achieved in the same quarter.
Boston Scientific Corporation Net Income in the 1 quarter 2026 grew year on year by 99.26%, while most of its competitors have experienced a contraction in net income by -31.09 %.
Boston Scientific's Comment on Competition and Industry Peers
The company operates in a competitive environment across its business segments, product lines, and markets, facing competition from both global and local manufacturers. Competitors include large manufacturers with diverse product lines, medical device companies with limited or specialized product offerings, and low-cost manufacturers, particularly in China, where domestic companies may have advantages as local suppliers. Additional competition comes from non-medical device companies providing alternative therapies. The company competes based on factors such as ease of use, comparative effectiveness, reliability, physician familiarity, price, value, and efficiency. Success depends on delivering differentiated clinical and economic outcomes, developing or acquiring innovative technologies, protecting intellectual property, obtaining regulatory approvals, maintaining quality systems, and implementing effective marketing strategies.
Company's competitiveness improved within Overall company, with revenue growth of 11.6 % and its market share increased to approx. 6.47 %. << More on BSX Market Share.
*Market share is calculated based on total revenue.
News about Boston Scientific Corporation Contracts
March 22, 2024
In a significant development for the medical technology industry, Axonics, Inc. announced that its stockholders have voted in favor of adopting the merger agreement with Boston Scientific Corporation. This decision marks a crucial step towards solidifying the partnership and signifies the market s confidence in the potential benefits that lie ahead. Moreover, amidst a challenging economic climate, Boston Scientific has managed to outperform its competitors, displaying impressive revenue growth and profitability.Assessing the Merger Agreement:Axonics stockholders displayed overwhelming support for the merger, with a majority of the shares voting in favor of adopting the agreement. This collaboration between A...
Publicly Traded Peers of Boston Scientific Corporation
Icad Inc Share Performance
+4.88%
30 Days
Icad Inc
Profile
Icad Inc operates on a business model that focuses on the development and commercialization of innovative cancer detection and therapy solutions. They primarily generate revenue through the sale of their advanced medical devices and software solutions to hospitals, clinics, and research institutions worldwide. Their business strategy revolves around continuous innovation, strategic partnerships, and a commitment to providing effective tools for early detection and treatment of cancer.
Catheter Precision Inc is a medical device manufacturing company that specializes in the production of catheters and related components. The company follows a business-to-business (B2B) model, supplying its products to healthcare institutions, hospitals, and other medical device companies. With its focus on precision and quality, Catheter Precision Inc aims to provide innovative and reliable solutions for various medical procedures involving catheters.
Integra Lifesciences Holdings Corp's business model revolves around developing, manufacturing, and selling medical devices and instruments to healthcare providers.
Livanova Plc is a global medical technology company that focuses on developing and delivering innovative solutions for patients with cardiovascular diseases and neuropsychiatric disorders. Through their diverse portfolio, they offer products and therapies that encompass surgical heart valves, cardiac rhythm management, and neuromodulation. Livanova adopts a patient-centric approach, collaborating with healthcare professionals to improve patient outcomes and enhance quality of life.
Penumbra Inc operates on a business model that focuses on the development and manufacturing of innovative medical devices. They aim to provide cutting-edge technologies and solutions to improve patient outcomes in various medical fields. The company primarily generates revenue through the sales of their medical devices to healthcare professionals and institutions worldwide.
Sources:
Boston Scientific Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Boston Scientific Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
